AEON Biopharma (AEON) Cash & Equivalents (2021 - 2026)

AEON Biopharma has reported Cash & Equivalents for 5 years, with the latest figure at $3.0 million in Q4 2025.

• Quarterly Cash & Equivalents rose 22976.92% year-over-year to $3.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.0 million (up 22976.92% YoY) and the FY2025 annual result came in at $3.0 million, up 22976.92% from the prior year.
• Cash & Equivalents declined to $3.0 million in Q4 2025 per AEON's latest filing, from $5.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $16.2 million in Q3 2023 and troughed at $7758.0 in Q2 2022.
• A 5-year average of $3.5 million and a median of $1.3 million in 2021 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents surged 58176.59% in 2023, then plunged 99.75% in 2024.
• Over 5 years, Cash & Equivalents stood at $497412.0 in 2021, then surged by 1859.34% to $9.7 million in 2022, then slumped by 47.08% to $5.2 million in 2023, then slumped by 99.75% to $13000.0 in 2024, then soared by 22976.92% to $3.0 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $3.0 million, $5.9 million, and $8.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.